Drug Trial Radar · NCT07904871
Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Nov 1, 2028
Study completion Nov 1, 2029
Sponsor
- Lead sponsor
- First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ruijin Hospital; The First Affiliated Hospital of Zhengzhou University; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy, safety, and feasibility of peri-transplant gecacitinib in patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Myelofibrosis is a bone marrow disorder that can cause reduced blood cell production, enlargement of the spleen, and other complications. Allogeneic stem cell transplantation offers a potential cure, but its benefits may be limited by graft-versus-host disease (GVHD), disease relapse, and transplant-related complications. This is a multicenter, prospective, open-label, single-arm clinical study. Participants will receive gecacitinib before, during, and after transplantation, together with standard transplantation care and GVHD prophylaxis. The primary objective is to evaluate GVHD-free, relapse-free survival (GRFS) at 1 year after transplantation. GRFS measures survival without severe acute GVHD, chronic GVHD requiring systemic immunosuppressive treatment, disease relapse or progression, or death. The study plans to enroll approximately 46 participants, with 43 expected to be evaluable for the primary endpoint. Participants will be followed for up to 2 years after transplantation. Secondary assessments include overall survival, progression-free survival, GVHD, disease relapse, non-relapse mortality, hematopoietic engraftment, treatment feasibility, and safety.
Conditions
- Myelofibrosis
- Primary Myelofibrosis (PMF)
- Secondary Myelofibrosis
Interventions
Peri-Transplant GecacitinibDrug
Gecacitinib will be administered orally starting on Day -14 before allogeneic hematopoietic stem cell transplantation (allo-HSCT) and continued throughout conditioning, transplantation, and the post-transplant period. The initial dose will be 50 mg twice daily (BID) for participants with baseline platelet counts ≥50 × 10\^9/L or 50 mg once daily (QD) for those with platelet counts below 50 × 10\^9/L. After hematopoietic engraftment, dose escalation up to 100 mg BID may be considered based on hematologic recovery, treatment tolerability, and disease control. Dose reductions, temporary interruptions, and treatment discontinuation will follow protocol-defined criteria for adverse events, infections, organ dysfunction, and drug interactions. Treatment may continue for up to 1 year after transplantation. All participants will receive standard transplantation care and GVHD prophylaxis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1-Year GVHD-Free, Relapse-Free Survival (GRFS)Time frame: From transplantation (Day 0) to 12 months after transplantation
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.